Click on the links or scroll down the page for information about work currently in progress by category. Please note that information summarised on this page is subject to change.
We produce prescribing guidance and other medicines resources to help patients and healthcare professionals in Wales make sure that medicines are used effectively and appropriately. When we produce these resources, we think it's important that people who might be affected by them have a chance to tell us their views.
We ask patients and carers, patient organisations, prescribers and other healthcare professionals to comment on the resources we're developing. We'd like your views on the resources we're currently working on, listed below. You don't need to comment on the whole document; only on parts that seem relevant to you.
Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.
Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.
We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.
Medicine name: cytisine Reference number: 3708 Indication: Smoking cessation and reduction of cravings in smokers willing to stop smoking. The treatment goal of cytisine is the permanent cessation of use of nicotine-containing products. Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form Submission deadline: 01/06/2024 AWMSG meeting date: 09/07/2024 |
Medicine name: emtricitabine/tenofovir alafenamide fumarate (Descovy®) Reference number: 2566 Indication: Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at‑risk men who have sex with men, including adolescents (with body weight at least 35 kg). Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form Submission deadline: 07/05/2023 |
Title: All Wales Common Ailments Service formulary – Monograph for urinary tract infection in women Status: Consultation completed Remit: In August 2023, the latest iteration of the ‘All Wales Common Ailments Service formulary’ document was published following consultation and AWMSG endorsement. The Welsh Medicines Advice Service (WMAS) are now looking to add an additional monograph on urinary tract infections (UTIs) in women. Estimated publication date: March 2024-May 2024 |
Title: Initial clinical management of nicotine withdrawal in adults in secondary care Status: Consultation completed Remit: This is an update to the document ‘Initial clinical management of adult smokers in secondary care’. The document gives information and guidance on the initiation of nicotine replacement therapy (NRT) in secondary care settings in NHS Wales, for management of nicotine withdrawal in adults who smoke. It has been reviewed and updated to include information on the use of vapes. Estimated publication date: September 2024-November 2024 |
Title: All Wales guidance for penicillin allergy de-labelling Status: Consultation completed Remit: This document provides information and guidance on the identification and removal of penicillin allergy labels in adults who have not experienced a true hypersensitivity reaction. This guidance is only intended for use in patients reporting a penicillin allergy in secondary care settings in NHS Wales. Estimated publication date: March 2024-May 2024 |
Title: Back-up antibiotic prescribing: Good practice guide Status: Consultation completed Remit: The aim of this document is to provide an All-Wales Good Practice Guide for the implementation of back-up prescribing strategies in primary and community care. It contains advice on when back-up prescribing should be considered, the strategies available and how this should be documented. |
One Wales Medicine re-assessment Reference number: OW21 Indication: As off-label treatment of immune checkpoint inhibitor induced grade 2-4 enterocolitis, where symptoms have not responded to first line immunosuppression with corticosteroids or require multiple challenge with corticosteroids. Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 03/06/2024 OWMAG date: 19/08/2024 AWMSG date: 11/09/2024 |
One Wales Medicine re-assessment Medicine name: vedolizumab (Entyvio®) Reference number: OW22 Indication: As off-label treatment of immune checkpoint inhibitor induced grade 2-4 enterocolitis, where symptoms have not responded to first line immunosuppression with corticosteroids or require multiple challenge with corticosteroids. Vedolizumab is an option for grade 3-4 enterocolitis where infliximab is unsuitable. Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 03/06/2024 OWMAG date: 19/08/2024 AWMSG date: 11/09/2024 |
One Wales Medicine assessment Medicine name: nivolumab Reference number: OW28 Indication: As off-label monotherapy for patients with oesophageal and gastric cancer with high microsatellite instability or mismatch repair deficiency, used in palliative care setting as first line treatment. Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 08/12/2023 OWMAG date: 18/03/2024 |
Title: Review of AWMSG processes to support medicines access in NHS Wales Summary: Revision of processes to improve access to medicines Estimated publication date: Summer/Autumn 2024 Document: Review of AWMSG processes to support medicines access in NHS Wales (PDF, 54Kb) |
Title: AWMSG annual report 2023-2024 Summary: Review of the activities and achievements of the All Wales Medicine Strategy Group (AWMSG) between April 2023 and March 2024. Estimated publication date: September 2024 |
Title: IPFR annual report 2023-2024 Summary: Review of Individual Patient Funding Request activity in Wales between April 2023 and March 2024. Estimated publication date: September 2024 |